The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax)

Al-Batran, S-E.; Hozaeel, Wael; Tauchert, F.K.; Hofheinz, Ralf–Dieter; Hinke, Axel; Windemuth-Kieselbach, C.; Hübner, Andreas; Burmester, Martin; Koenigsmann, Michael; Wiegand, Jörg; Hausen, Gerrit zur; Linsse, Burkhard; Kuhl, Rosemarie; Pauligk, Claudia

doi:10.1093/annonc/mdv129

Cited by 50 publications

(32 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There were 7 studies covering 2 topics each [3,13,14,15,16,17,18] and 7 meta-analyses [19,20,21,22,23,24,25]. 20 studies (29.4%) were from Europe [3,5,9,10,11,12,15,22,26,27,28,29,30,31,32,33,34,35,36,37,38,] 20 from the US [4,14,17,19,20,24,39,40,41,42,43,44,45,46,47,48,49,50,51,52], 3 studies (4.4%) from US plus Europe [23,53,54], 6 studies (8.8%) from Japan [16,55,56,57,58,59], 6 studies (8.8%) from China [18,25,60,61,62,63], 2 studies (3.0%) from Hong Kong [13,64,65], 3 studies (4.4%) from Canada [66,67,68], 3 studies (4.4%) from India [21,69,70] and 5 studies (7.4%) from other countries [7,71,72,73,74]. 21 studies (30.9%) used the National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) scale for assessment of OM.…”

Section: Resultsmentioning

confidence: 99%

“…Resource use associated with OM was reported in 3 studies concerning patients with HSCT [3,7,17], 2 studies with HNC [4,43] and 1 study with chemotherapy [42] and 1 study with mixed tumor types and treatment [45]. The impact of OM on health-related quality of life (HRQoL) was investigated in 1 study in patients with HSCT [35], 5 studies with HNC [18,52,53,66,72], 6 studies with chemotherapy [15,16,26,27,41,74], and 4 studies with mixed tumor types and treatment [13,33,64,65,69]. …”

Section: Resultsmentioning

confidence: 99%

“…The most commonly used were the FACT-G (Functional Assessment of Cancer Therapy-General score) in 5 studies [27,35,53,64,65,74], the EORTC QLQ-C30 (European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire) in 4 studies [26,33,66,72] and the EORTC QLQ-H&N35 (European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire for Head and Neck cancer patients) in 3 studies [18,33,72]. The available PRO scores were rarely comparable due to different patient groups, different time points chosen during or after therapy, and different instruments used for HRQoL measurement.…”

Section: Resultsmentioning

confidence: 99%

“…Patients with chemotherapy for solid tumors showed statistically significant effects on the physical and emotional component of the FACT-G score when they developed OM [27,74]. The EORTC QLQ-C30 score changed significantly in patients with metastatic cancer and stomatitis [26]. …”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Burden of Oral Mucositis: A Systematic Review and Implications for Future Research

et al. 2018

View full text Add to dashboard Cite

Background: Surprisingly little is known about the burden of oral mucositis (OM). We provide a systematic review of studies on the burden of OM (incidence, economic impact, health-related quality of life (HRQoL)). Methods: Systematic literature searches were made in BIOSIS, EMBASE, and MEDLINE. Inclusion criteria were studies on OM in hematology/oncology patients of ≥ 18 years, journal articles, English language, and published between 2000 and 2016; OM treatment studies were excluded. Quality assessment was performed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Results: We screened 4,996 hits, and identified 68 studies of which 13 were without transparency on OM grading. The evidence level of 65 studies was rated ‘low' or ‘very low' in 58.5%, ‘moderate' in 20% and ‘high' in 21.5%. Mean value of incidence (7 studies) was 83.5% for all grades of OM with hematopoietic stem cell transplantation. OM incidence for all grades in head and neck cancer patients was 59.4-100%. Considering the economic impact, 16 studies showed highly variable numbers. HRQoL was measured in 16 studies using 13 different instruments. Statistically significant changes in HRQoL scores were demonstrated. Conclusion: OM is common, burdensome, costly and imposes major reductions in HRQoL. However, from a quality standpoint, the level of current evidence in OM is disappointing. The field needs continued attention to address methodological challenges.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Burden of Oral Mucositis: A Systematic Review and Implications for Future Research

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Furthermore, for patients with progressive disease following first-line treatment for advanced gastro-oesophageal cancer, quality of life and maintaining performance status are key therapeutic goals and the toxicity of chemotherapy must not be overlooked. In these studies of second-line or subsequent chemotherapy, treatment toxicity was significant, particularly gastrointestinal symptoms, which are known to adversely impact quality of life [Al-Batran et al 2015] (Table 1).…”

Section: Current Standard Of Carementioning

confidence: 99%

Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma

Young

Smyth

Chau

2015

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Ramucirumab, a fully humanized monoclonal antibody directed against vascular endothelial growth factor receptor 2, is the first targeted agent to have demonstrated an improvement in survival, as a single agent or in combination, in a molecularly unselected population in gastro-oesophageal cancer. Now that second-line treatment is routinely considered for patients with advanced gastro-oesophageal cancer, ramucirumab, with its favourable toxicity profile compared with cytotoxic treatment, provides a valuable additional treatment option.

show abstract

Tumor Cells‐Selective Bionic Nanodevice Exploiting Heparanase Combats Metastatic Breast Cancer

Lang

Wei

Dong

et al. 2018

Adv Funct Materials

View full text Add to dashboard Cite

The clinical application of the cytotoxic chemotherapeutic agents in the treatment of metastatic breast cancer is limited by their poor selectivity to cancer cells. In this work, a bionic nanodevice consisting of the docetaxel (DTX)‐heparan sulfate (HS) conjugate (HS‐DTX) micelle with a red blood cells membrane (RBC) coating on its surface, termed as rHS‐DTX, is first constructed. It is found that the cytotoxicity of DTX is concealed by HS in human mammary epithelial Michigan Cancer Foundation (MCF)‐10A cells but restored in human mammary cancer MCF‐7 cells because HS is hydrolyzed by heparanase (Hpa), which is overexpressed only in MCF‐7 but not MCF‐10A cells. The RBC coating enhances the cellular uptake of HS‐DTX and endows it with the long circulating ability in blood. In the MCF‐7 metastatic breast cancer mice model, rHS‐DTX exhibits 6.35‐fold higher intratumor DTX accumulation than the free DTX injection and achieves a tumor inhibiting rate of 98.2% and a lung metastasis suppression rate of 99.6%. No severe toxicity is observed in the major organs and blood of mice treated with rHS‐DTX. In summary, rHS‐DTX can provide a promising strategy for targeting therapy of metastatic breast cancer by improving the tumor‐suppressing efficacy of DTX.

show abstract

The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax)

Abstract: This study was registered at Deutsches Krebsstudienregister (DKSR, primary registry in the WHO Registry Network) with the ID 527.

Cited by 50 publications

References 16 publications

Burden of Oral Mucositis: A Systematic Review and Implications for Future Research

Burden of Oral Mucositis: A Systematic Review and Implications for Future Research

Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma

Tumor Cells‐Selective Bionic Nanodevice Exploiting Heparanase Combats Metastatic Breast Cancer

Contact Info

Product

Resources

About